Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) announced its earnings results on Thursday. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.43, FiscalAI reports.
Oramed Pharmaceuticals Stock Performance
Shares of NASDAQ:ORMP opened at $3.71 on Monday. Oramed Pharmaceuticals has a 12-month low of $2.25 and a 12-month high of $5.47. The business’s fifty day simple moving average is $4.36 and its 200-day simple moving average is $4.05. The company has a market capitalization of $154.34 million, a PE ratio of 0.60 and a beta of 1.31.
Insider Buying and Selling at Oramed Pharmaceuticals
In related news, COO Joshua Hexter sold 30,000 shares of the firm’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $4.51, for a total transaction of $135,300.00. Following the sale, the chief operating officer owned 1,328,130 shares of the company’s stock, valued at $5,989,866.30. This trade represents a 2.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Avraham Gabay sold 20,000 shares of Oramed Pharmaceuticals stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $4.51, for a total value of $90,200.00. Following the completion of the transaction, the chief financial officer owned 861,076 shares in the company, valued at $3,883,452.76. This trade represents a 2.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 20.77% of the company’s stock.
Analyst Upgrades and Downgrades
ORMP has been the subject of a number of research reports. Wall Street Zen lowered Oramed Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. Weiss Ratings upgraded Oramed Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, October 23rd. One investment analyst has rated the stock with a Buy rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy”.
Read Our Latest Research Report on Oramed Pharmaceuticals
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing oral drug-delivery technologies. Its platform is designed to protect protein-based medicines as they pass through the digestive system and support their absorption, with the aim of delivering medicines by mouth that have traditionally been given by injection. The company’s research has focused on oral treatments for metabolic conditions, including ORMD-0801, an oral insulin candidate, and an oral GLP-1 candidate. These products are investigational; Oramed does not market them as approved treatments.
Featured Stories
- Five stocks we like better than Oramed Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
